Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD study of gosuranemab in healthy subjects
NCT02294851Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in tauopathy, Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) comparing Gosuranemab SAD Cohorts with Placebo (2 arms). Primary endpoint: Safety and tolerability at 8 months. Started Dec 2014; status: completed.
02
Drugs
gosuranemab
03
Conditions
tauopathyAlzheimer's disease (AD)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02294851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294851.